Pharmaceuticals
KAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP'S GLOBAL HEALTHCARE 'OPEN HOUSE' VIRTUAL CONFERENCE
SYDNEY, Jan. 25, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be speaking at the Edison Group 'Open House' Event, to be held virtually from25-27 January 2022. Kazia ...
2022-01-25 21:00
3174
Senhwa's Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations
TAIPEI and SAN DIEGO, Jan. 25, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced today that the US Food and Drug Administration (FDA) has granted Fast Track...
2022-01-25 20:00
1947
Sequanta selects Olink® Explore 3072 to analyze new cohort study in China
SHANGHAI, Jan. 25, 2022 /PRNewswire/ -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that Sequanta Technologies, a leading multi-omics service provider based inChina, will use Olink® Explore 3072 to analyze the samples to serve a new large scale cohort study in China. Since 2021, Sequa...
2022-01-25 19:36
1374
2022 Japan Prize Laureates Announced
TOKYO, Jan. 25, 2022 /PRNewswire/ -- The Japan Prize Foundation announced the winners of the 2022 Japan prize onJanuary 25. Prof. Katalin Kariko (Hungary/USA ) and Prof.Drew Weissman (USA) are co-winners of the Japan Prize in the field of "Materials and Production," and Prof.Christopher Field (USA...
2022-01-25 14:00
1616
ImmVira's New-Generation Vector Poised to Enable CAR-T Treatment for Solid Tumors
SHENZHEN, China, Jan. 24, 2022 /PRNewswire/ -- Demonstrating innovation leadership on a global level, ImmVira announced that, its custom-designed new-generation oncolytic herpes simplex virus ("oHSV") vector enabling CAR-T treatment for solid tumors has started pilot-scale manufacturing and Phar...
2022-01-25 08:30
1542
Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826
SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing in its phase II clinical trial of KX-826("p...
2022-01-24 21:47
2545
Samsung Biologics Reports Fourth Quarter & Fiscal Year 2021 Financial Results
* Q4'21 revenue of KRW 444.3 billion increased 18% compared to Q4'20. * Q4'21 operating profit of KRW 128.8 billion increased 39% compared to Q4'20. * FY'21 revenue of KRW 1,568.0 billion, an increase of 35% compared to FY'20. * FY'21 operating profit of KRW 537.3 billion, an increase of 84% ...
2022-01-24 16:25
1980
Harbour BioMed Announces Dosing of First Patient in Combination Therapy Phase Ib/IIa Trial of Next-Generation Anti-CTLA-4 Antibody
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, it has successfully completed the dosing of first patient in phase Ib/IIa trial at the stage of dose expansion of its anti-CTLA-4 antibody (HBM4003) in ...
2022-01-24 15:39
1751
HanAll Biopharma Reports Full-Year 2021 Results and Provides Business Update
* 2021 sales of KRW 101.6 billion for a 15% increase from 2020 * 2021 operating profit of KRW 10.1 billion grew by 70% from 2020 * Increasing milestone payments and revenues from R&D activities are reinvested into new R&D programs SEOUL, South Korea, Jan. 20, 2022 /PRNewswire/ -- [Busines...
2022-01-20 22:00
2105
Hinova Announces First Patient Dosed in a Phase I Clinical Trial of HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
MELBOURNE, Australia, Jan. 20, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, today announced that the first patient with m...
2022-01-20 20:28
1827
Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer
TAIPEI and SAN DIEGO, Jan. 20, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Des...
2022-01-20 20:00
1955
Nippon Express (Belgium) Acquires GDP Certification for Facility in Brussels Airport's Cargo Area
TOKYO, Jan. 20, 2022 /PRNewswire/ -- Nippon Express (Belgium) N.V./S.A. (hereinafter "NX Belgium"), a company of the Nippon Express Holdings, Inc. Group, has obtained Good Distribution Practice (GDP) certification, effective December 21, 2021, for air and ground forwarding operations, inclusive of...
2022-01-20 15:00
1636
Neurophth Therapeutics Receives IND Clearance to Initiate Clinical Trial for China AAV-ND4 Gene Therapy NR082 in Leber Hereditary Optic Neuropathy
WUHAN, China and SAN DIEGO, Jan. 19, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth"), today announced receiving the U.S. Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application on thein-vivo gene replacement thera...
2022-01-19 22:30
1805
Qilian International Holding Group Limited Receives Approval for the Sale of its Newly Developed Nitrofurantoin Enteric-coated Tablets
JIUQUAN, China, Jan. 19, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), aChina-based pharmaceutical and chemical products manufacturer, today announced that the Company received approval from Gansu Provin...
2022-01-19 20:30
1715
ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data
SHENZHEN, China, Jan. 18, 2022 /PRNewswire/ -- ImmVira's breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has recently completed first 2 cohorts dose-escalation of U.S. Phase I clinical study, and demonstrated good saf...
2022-01-19 08:30
1529
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors
SHANGHAI and GAITHERSBURG, Md., Jan. 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in itsChina phase ...
2022-01-18 21:00
1517
CN Energy Signs Operation & Management Agreement; Enters Multi-Billion Dollar Pharmaceutical Excipients Market
LISHUI, China, Jan. 18, 2022 /PRNewswire/ -- CN Energy Group. Inc. (the "Company") today announced that its subsidiary Hangzhou Forasen Technology Co., Ltd. signed an operation and management ("O&M") agreement (the "Agreement") with HuaiNan JiaHe New Materials Co., Ltd. ("JiaHe") and JiaHe's acti...
2022-01-18 21:00
1599
MindRank Begins IND-enabling Studies of its first AI-designed Drug, 8 Months After Program Initiation
HANGZHOU, China, Jan. 18, 2022 /PRNewswire/ -- MindRank AI, an artificial intelligence (AI) driven biotech company, today announced that the company has nominated a preclinical candidate (PCC) for an important class B GPCR drug target, 8 Months After Program Initiation. Historically, the developm...
2022-01-18 17:17
1374
InnoCare and Keymed Jointly Announce Dosing of First Patient in Clinical Trial of CD20xCD3 Bispecific Antibody CM355
BEIJING, Jan. 18, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX: 02162) jointly announced today that the first patient inChina has been dosed in clinical trial of CM355, a CD20xCD3 bispecific antibody developed by a joint venture between the two companies, for th...
2022-01-18 14:51
1947
WuXi Biologics Completes GMP Inspection by South Korea's Ministry of Food and Drug Safety for Drug Substance Facility
* WuXi Biologics completes the first GMP inspection in 2022, demonstrating the company's premier quality system is in full compliance with global regulatory requirements. WUXI, China, Jan. 17, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access ...
2022-01-18 10:50
2072
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
5310
